Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Changing fortunes: Is Biotech giant CSL’s $10 billion write-down a comeback story?
51+ min ago (589+ words) August 18, 2026 — 3:51pm Rarely has an Australian company booked a write-down of the magnitude of biotechnology giant CSL’s $10 billion. It is almost as extraordinary to see the share price of a company the size of CSL – $74.2 billion – leap by more than 16 per…...
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook — TradingView News
9+ hour, 55+ min ago (174+ words) OmniAb Inc. (OABI, Financials) shares soared almost 18% in premarket trade after the company raised its cash forecast for 2026 on the back of recent license and business-development agreements. The business now intends to complete the year with $49 million to $53 million in…...
GenBio Inc. to Participate in the 2026 Asia Bio Partnering Forum in Singapore - Lohud | The Journal News
10+ hour, 23+ min ago (164+ words) GenBio will meet with pharmaceutical and biotechnology leaders in Singapore to discuss its scientific platform and strategic opportunities. ALISO VIEJO, CA, UNITED STATES, August 1, 2026 /EINPresswire.com/ — GenBio Inc., a privately held biotechnology company developing therapeutic and health applications from rare,…...
Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development
9+ hour, 25+ min ago (499+ words) TheNewswire Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development Vancouver, British Columbia – TheNewswire - August 17, 2026 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCF”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage…...
Latham Advises Frazier Life Sciences on Private Placement Financing in Connection With Fulcrum Therapeutics and Slate Medicines Merger
3+ hour, 54+ min ago (191+ words) Latham Advises Frazier Life Sciences on Private Placement Financing With Fulcrum Slate Merger Latham & Watkins LLP Fulcrum Therapeutics, Inc. (Fulcrum) (Nasdaq: FULC) and Slate Medicines, Inc. (Slate), a biotechnology company developing next-generation therapeutics for the treatment of migraine, have announced…...
Biosolutions could help Japan become a global bioeconomy powerhouse, new report finds
4+ hour, 42+ min ago (285+ words) 18 Aug, 2026, 10:00 CST A new report, The Value of Biosolutions: Growth and Prosperity to 2035 – Japan Edition, highlights how biosolutions could strengthen Japan's position as a global biomanufacturing hub and support its ambition to realize the world's most advanced bioeconomy by 2030. However,…...
Sanofi offloads Blueprint staff, Merck KGaA trims headcount in Massachusetts
7+ hour, 49+ min ago (12+ words) FirstWord Pharma...
Ingenia Therapeutics lists on KOSDAQ, targets global antibody market
2+ hour, 3+ min ago (190+ words) Advancing pipeline with TIE-body and LCIDEC to validate vascular antibody technology worldwide Vascular disease antibody new drug corporations Ingenia Therapeutics was listed on the KOSDAQ market on the 18th. Following a retina disease treatment that achieved global technology transfer, it plans…...
Fulcrum Therapeutics to Merge With Slate Medicines in $245 Million Backed Migraine Play — BigGo Finance
8+ hour, 13+ min ago (469+ words) Fulcrum Therapeutics (FULC) has agreed to merge with privately held Slate Medicines in an all-stock transaction that will create a Nasdaq-listed biotech focused on next-generation migraine treatments, the companies announced Monday. The combined company will operate under the Slate Medicines…...
After failure in sickle cell, Fulcrum merges with Slate
12+ hour, 59+ min ago (193+ words) Blood disorder specialist Fulcrum Therapeutics has agreed to what amounts to a reverse merger with Slate Medicines, a privately held biotech focused on next generation therapies for migraine. The merged company is expected to be led by Slate Medicines CEO…...